A first-of-its-kind gene therapy that can restore hearing in children born deaf has just cleared its final hurdle—and, in a ...

Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene ...

Cell and gene therapies have a huge curative potential but come with a large price tag that can result in access barriers. At ...

Regeneron’s drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness.

Astellas Pharma has done some spring cleaning of its pipeline, dropping two phase 1 candidates and slamming the brakes on a ...

The agency's decision is based on results from a clinical trial in which the treatment improved hearing in 80 percent of the ...

The agreement is set to expand LEO Pharma’s pipeline in rare dermatology.

Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 ...

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an ...

Kelly Anne is a deputy editor at Forbes Advisor overseeing the development of various initiatives, including newsletters, ...

CGT Global, a leading accelerator of innovation, implementation and access to cell and gene therapies, announced today the appointment of Charlotte Ivancic to its Board of Advisors. Ms. Ivancic brings ...

Ocugen Inc. (NASDAQ: OCGN) is one of the best biotech penny stocks to buy in 2026. On April 1, Ocugen completed dosing ahead ...